Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Ocular Therapeutix, Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 10.20 · gapped above the open, then crossed back over prior close. High/low 10.95 at 7:00 am ET, 10.10 at 5:30 pm ET.
Ocular Therapeutix, Inc has 2 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either Ocular Therapeutix, Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
OCUL (Ocular Therapeutix, Inc) has 2 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For example, for the years ended December 31, 2025, 2024 and 2023, three SDs accounted for a combined percentage of our total revenue of 75%, 77%, and 85%, respectively.”
$39M relationship
basisOCUL fy2025 · closed 2025-12 $52M
FILING10-K0001104659-26-010664cik 0001393434
“For example, for the years ended December 31, 2025, 2024 and 2023, one in-market customer accounted for approximately 17%, 18%, and 19% of our gross sales of DEXTENZA before adjustments, respectively.”
$9M relationship
basisOCUL fy2025 · closed 2025-12 $52M
FILING10-K0001104659-26-010664
“Our net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.”
FILING10-K0001104659-26-010664cik 0001393434
“Our net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.”
FILING10-K0001104659-26-010664cik 0001393434
“Our net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.”
FILING10-K0001104659-26-010664cik 0001393434
“All of our collaboration revenue was attributable to the performance obligation under our license agreement with AffaMed to conduct a Phase 2 clinical trial of OTX-TIC, which we fully satisfied in 2025.”
FILING10-K0001104659-26-010664cik 0001393434
“As of December 31, 2025, we had cash and cash equivalents of $737.1 million, and outstanding debt with a principal amount of $82.5 million under a credit and security agreement, or the Barings Credit Agreement, with Barings Finance LLC, or Barings, as administrative agent, and the lenders party thereto, or the Barings Credit Facility.”
FILING10-K0001104659-26-010664cik 0001393434
“We have in-licensed a significant portion of our intellectual property from Incept, an intellectual property holding company, under an amended and restated license agreement, or the License Agreement, that we entered into with Incept in January 2012, which was most recently amended in September 2018.”
FILING10-K0001104659-26-010664cik 0001393434
Watchlist prices, news filtered to it, and its next report on your desk.